ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
2
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
2
U.S. (TOLL FREE)
+1 (315) 215-3225
Global PD-L1 Biomarker Testing Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-6F9402
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global PD L1 Biomarker Testing Market Size Status and Forecast 2022
BUY CHAPTERS

Global PD-L1 Biomarker Testing Market Research Report 2025

Code: QYRE-Auto-6F9402
Report
June 2025
Pages:80
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Agilent Technologies
Roche
Merck
Bristol–Myers Squibb
Astrazeneca plc
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences

PD-L1 Biomarker Testing Market Size

The global market for PD-L1 Biomarker Testing was valued at US$ 2815 million in the year 2024 and is projected to reach a revised size of US$ 27020 million by 2031, growing at a CAGR of 38.7% during the forecast period.

PD-L1 Biomarker Testing Market

PD-L1 Biomarker Testing Market

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances. Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart). PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies. PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The PD‑L1 biomarker testing market is being propelled by the rapid expansion of immune checkpoint inhibitor therapies, particularly those targeting the PD‑1/PD‑L1 axis, which have shown remarkable clinical success in treating various advanced cancers—spurring widespread demand for stratifying patients based on PD‑L1 expression to optimize treatment outcomes. Additionally, the shift toward precision medicine has heightened the importance of molecular diagnostics. Clinicians and pharmaceutical developers are increasingly emphasizing personalized approaches, using PD‑L1 testing to guide therapeutic decisions and enable companion diagnostics—especially as diagnostic technologies advance to include automated IHC systems, NGS platforms, and AI-enhanced analysis .
Despite these positive trends, the PD‑L1 testing landscape faces significant obstacles due to a lack of standardization across protocols, assay clones, scoring systems, and cut-off thresholds. This inconsistency manifests in discordant results (with variability rates reported between 19–32% across different assays), undermining diagnostic reliability and complicating clinical decision-making. Moreover, high costs associated with advanced testing techniques (IHC, NGS) and uneven reimbursement frameworks create economic barriers, particularly in developing regions, impeding broad accessibility and exacerbating healthcare disparities.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2024 is about 21.68%. PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2024 is about 52.7%.
This report aims to provide a comprehensive presentation of the global market for PD-L1 Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-L1 Biomarker Testing.
The PD-L1 Biomarker Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global PD-L1 Biomarker Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-L1 Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of PD-L1 Biomarker Testing Market Report

Report Metric Details
Report Name PD-L1 Biomarker Testing Market
Accounted market size in year US$ 2815 million
Forecasted market size in 2031 US$ 27020 million
CAGR 38.7%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • PD-L1 (22C3)
  • PD-L1(28-8)
  • PD-L1 (SP142)
  • PD-L1 (SP263)
  • Other
Segment by Application
  • Hospital
  • Diagnostic Center
  • Others
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of PD-L1 Biomarker Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is PD-L1 Biomarker Testing Market growing?

Ans: The PD-L1 Biomarker Testing Market witnessing a CAGR of 38.7% during the forecast period 2025-2031.

What is the PD-L1 Biomarker Testing Market size in 2031?

Ans: The PD-L1 Biomarker Testing Market size in 2031 will be US$ 27020 million.

What is the PD-L1 Biomarker Testing Market share by application?

Ans: The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2024 is about 52.7%.

Who are the main players in the PD-L1 Biomarker Testing Market report?

Ans: The main players in the PD-L1 Biomarker Testing Market are Agilent Technologies, Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences

What are the Application segmentation covered in the PD-L1 Biomarker Testing Market report?

Ans: The Applications covered in the PD-L1 Biomarker Testing Market report are Hospital, Diagnostic Center, Others

What are the Type segmentation covered in the PD-L1 Biomarker Testing Market report?

Ans: The Types covered in the PD-L1 Biomarker Testing Market report are PD-L1 (22C3), PD-L1(28-8), PD-L1 (SP142), PD-L1 (SP263), Other

Recommended Reports

Cancer Diagnostics

Immunotherapy Markets

Biomarker Testing

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PD-L1 Biomarker Testing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 PD-L1 (22C3)
1.2.3 PD-L1(28-8)
1.2.4 PD-L1 (SP142)
1.2.5 PD-L1 (SP263)
1.2.6 Other
1.3 Market by Application
1.3.1 Global PD-L1 Biomarker Testing Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Diagnostic Center
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global PD-L1 Biomarker Testing Market Perspective (2020-2031)
2.2 Global PD-L1 Biomarker Testing Growth Trends by Region
2.2.1 Global PD-L1 Biomarker Testing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 PD-L1 Biomarker Testing Historic Market Size by Region (2020-2025)
2.2.3 PD-L1 Biomarker Testing Forecasted Market Size by Region (2026-2031)
2.3 PD-L1 Biomarker Testing Market Dynamics
2.3.1 PD-L1 Biomarker Testing Industry Trends
2.3.2 PD-L1 Biomarker Testing Market Drivers
2.3.3 PD-L1 Biomarker Testing Market Challenges
2.3.4 PD-L1 Biomarker Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top PD-L1 Biomarker Testing Players by Revenue
3.1.1 Global Top PD-L1 Biomarker Testing Players by Revenue (2020-2025)
3.1.2 Global PD-L1 Biomarker Testing Revenue Market Share by Players (2020-2025)
3.2 Global Top PD-L1 Biomarker Testing Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by PD-L1 Biomarker Testing Revenue
3.4 Global PD-L1 Biomarker Testing Market Concentration Ratio
3.4.1 Global PD-L1 Biomarker Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PD-L1 Biomarker Testing Revenue in 2024
3.5 Global Key Players of PD-L1 Biomarker Testing Head office and Area Served
3.6 Global Key Players of PD-L1 Biomarker Testing, Product and Application
3.7 Global Key Players of PD-L1 Biomarker Testing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 PD-L1 Biomarker Testing Breakdown Data by Type
4.1 Global PD-L1 Biomarker Testing Historic Market Size by Type (2020-2025)
4.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Type (2026-2031)
5 PD-L1 Biomarker Testing Breakdown Data by Application
5.1 Global PD-L1 Biomarker Testing Historic Market Size by Application (2020-2025)
5.2 Global PD-L1 Biomarker Testing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America PD-L1 Biomarker Testing Market Size (2020-2031)
6.2 North America PD-L1 Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America PD-L1 Biomarker Testing Market Size by Country (2020-2025)
6.4 North America PD-L1 Biomarker Testing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PD-L1 Biomarker Testing Market Size (2020-2031)
7.2 Europe PD-L1 Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe PD-L1 Biomarker Testing Market Size by Country (2020-2025)
7.4 Europe PD-L1 Biomarker Testing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific PD-L1 Biomarker Testing Market Size (2020-2031)
8.2 Asia-Pacific PD-L1 Biomarker Testing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2020-2025)
8.4 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America PD-L1 Biomarker Testing Market Size (2020-2031)
9.2 Latin America PD-L1 Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America PD-L1 Biomarker Testing Market Size by Country (2020-2025)
9.4 Latin America PD-L1 Biomarker Testing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PD-L1 Biomarker Testing Market Size (2020-2031)
10.2 Middle East & Africa PD-L1 Biomarker Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2020-2025)
10.4 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent Technologies
11.1.1 Agilent Technologies Company Details
11.1.2 Agilent Technologies Business Overview
11.1.3 Agilent Technologies PD-L1 Biomarker Testing Introduction
11.1.4 Agilent Technologies Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.1.5 Agilent Technologies Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche PD-L1 Biomarker Testing Introduction
11.2.4 Roche Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.2.5 Roche Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck PD-L1 Biomarker Testing Introduction
11.3.4 Merck Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.3.5 Merck Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Introduction
11.4.4 Bristol-Myers Squibb Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca PD-L1 Biomarker Testing Introduction
11.5.4 AstraZeneca Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.5.5 AstraZeneca Recent Development
11.6 Ono Pharmaceutical
11.6.1 Ono Pharmaceutical Company Details
11.6.2 Ono Pharmaceutical Business Overview
11.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Introduction
11.6.4 Ono Pharmaceutical Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.6.5 Ono Pharmaceutical Recent Development
11.7 Regeneron
11.7.1 Regeneron Company Details
11.7.2 Regeneron Business Overview
11.7.3 Regeneron PD-L1 Biomarker Testing Introduction
11.7.4 Regeneron Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.7.5 Regeneron Recent Development
11.8 Innovent
11.8.1 Innovent Company Details
11.8.2 Innovent Business Overview
11.8.3 Innovent PD-L1 Biomarker Testing Introduction
11.8.4 Innovent Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.8.5 Innovent Recent Development
11.9 Hengrui Medicine
11.9.1 Hengrui Medicine Company Details
11.9.2 Hengrui Medicine Business Overview
11.9.3 Hengrui Medicine PD-L1 Biomarker Testing Introduction
11.9.4 Hengrui Medicine Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.9.5 Hengrui Medicine Recent Development
11.10 Junshi Biosciences
11.10.1 Junshi Biosciences Company Details
11.10.2 Junshi Biosciences Business Overview
11.10.3 Junshi Biosciences PD-L1 Biomarker Testing Introduction
11.10.4 Junshi Biosciences Revenue in PD-L1 Biomarker Testing Business (2020-2025)
11.10.5 Junshi Biosciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Agilent Technologies
Roche
Merck
Bristol–Myers Squibb
Astrazeneca plc
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
List of Tables
 Table 1. Global PD-L1 Biomarker Testing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of PD-L1 (22C3)
 Table 3. Key Players of PD-L1(28-8)
 Table 4. Key Players of PD-L1 (SP142)
 Table 5. Key Players of PD-L1 (SP263)
 Table 6. Key Players of Other
 Table 7. Global PD-L1 Biomarker Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global PD-L1 Biomarker Testing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 9. Global PD-L1 Biomarker Testing Market Size by Region (2020-2025) & (US$ Million)
 Table 10. Global PD-L1 Biomarker Testing Market Share by Region (2020-2025)
 Table 11. Global PD-L1 Biomarker Testing Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 12. Global PD-L1 Biomarker Testing Market Share by Region (2026-2031)
 Table 13. PD-L1 Biomarker Testing Market Trends
 Table 14. PD-L1 Biomarker Testing Market Drivers
 Table 15. PD-L1 Biomarker Testing Market Challenges
 Table 16. PD-L1 Biomarker Testing Market Restraints
 Table 17. Global PD-L1 Biomarker Testing Revenue by Players (2020-2025) & (US$ Million)
 Table 18. Global PD-L1 Biomarker Testing Market Share by Players (2020-2025)
 Table 19. Global Top PD-L1 Biomarker Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-L1 Biomarker Testing as of 2024)
 Table 20. Ranking of Global Top PD-L1 Biomarker Testing Companies by Revenue (US$ Million) in 2024
 Table 21. Global 5 Largest Players Market Share by PD-L1 Biomarker Testing Revenue (CR5 and HHI) & (2020-2025)
 Table 22. Global Key Players of PD-L1 Biomarker Testing, Headquarters and Area Served
 Table 23. Global Key Players of PD-L1 Biomarker Testing, Product and Application
 Table 24. Global Key Players of PD-L1 Biomarker Testing, Date of Enter into This Industry
 Table 25. Mergers & Acquisitions, Expansion Plans
 Table 26. Global PD-L1 Biomarker Testing Market Size by Type (2020-2025) & (US$ Million)
 Table 27. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2020-2025)
 Table 28. Global PD-L1 Biomarker Testing Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 29. Global PD-L1 Biomarker Testing Revenue Market Share by Type (2026-2031)
 Table 30. Global PD-L1 Biomarker Testing Market Size by Application (2020-2025) & (US$ Million)
 Table 31. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2020-2025)
 Table 32. Global PD-L1 Biomarker Testing Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 33. Global PD-L1 Biomarker Testing Revenue Market Share by Application (2026-2031)
 Table 34. North America PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. North America PD-L1 Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 36. North America PD-L1 Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Europe PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Europe PD-L1 Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 39. Europe PD-L1 Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 40. Asia-Pacific PD-L1 Biomarker Testing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2020-2025) & (US$ Million)
 Table 42. Asia-Pacific PD-L1 Biomarker Testing Market Size by Region (2026-2031) & (US$ Million)
 Table 43. Latin America PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Latin America PD-L1 Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Latin America PD-L1 Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Middle East & Africa PD-L1 Biomarker Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 47. Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2020-2025) & (US$ Million)
 Table 48. Middle East & Africa PD-L1 Biomarker Testing Market Size by Country (2026-2031) & (US$ Million)
 Table 49. Agilent Technologies Company Details
 Table 50. Agilent Technologies Business Overview
 Table 51. Agilent Technologies PD-L1 Biomarker Testing Product
 Table 52. Agilent Technologies Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 53. Agilent Technologies Recent Development
 Table 54. Roche Company Details
 Table 55. Roche Business Overview
 Table 56. Roche PD-L1 Biomarker Testing Product
 Table 57. Roche Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 58. Roche Recent Development
 Table 59. Merck Company Details
 Table 60. Merck Business Overview
 Table 61. Merck PD-L1 Biomarker Testing Product
 Table 62. Merck Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 63. Merck Recent Development
 Table 64. Bristol-Myers Squibb Company Details
 Table 65. Bristol-Myers Squibb Business Overview
 Table 66. Bristol-Myers Squibb PD-L1 Biomarker Testing Product
 Table 67. Bristol-Myers Squibb Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 68. Bristol-Myers Squibb Recent Development
 Table 69. AstraZeneca Company Details
 Table 70. AstraZeneca Business Overview
 Table 71. AstraZeneca PD-L1 Biomarker Testing Product
 Table 72. AstraZeneca Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 73. AstraZeneca Recent Development
 Table 74. Ono Pharmaceutical Company Details
 Table 75. Ono Pharmaceutical Business Overview
 Table 76. Ono Pharmaceutical PD-L1 Biomarker Testing Product
 Table 77. Ono Pharmaceutical Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 78. Ono Pharmaceutical Recent Development
 Table 79. Regeneron Company Details
 Table 80. Regeneron Business Overview
 Table 81. Regeneron PD-L1 Biomarker Testing Product
 Table 82. Regeneron Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 83. Regeneron Recent Development
 Table 84. Innovent Company Details
 Table 85. Innovent Business Overview
 Table 86. Innovent PD-L1 Biomarker Testing Product
 Table 87. Innovent Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 88. Innovent Recent Development
 Table 89. Hengrui Medicine Company Details
 Table 90. Hengrui Medicine Business Overview
 Table 91. Hengrui Medicine PD-L1 Biomarker Testing Product
 Table 92. Hengrui Medicine Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 93. Hengrui Medicine Recent Development
 Table 94. Junshi Biosciences Company Details
 Table 95. Junshi Biosciences Business Overview
 Table 96. Junshi Biosciences PD-L1 Biomarker Testing Product
 Table 97. Junshi Biosciences Revenue in PD-L1 Biomarker Testing Business (2020-2025) & (US$ Million)
 Table 98. Junshi Biosciences Recent Development
 Table 99. Research Programs/Design for This Report
 Table 100. Key Data Information from Secondary Sources
 Table 101. Key Data Information from Primary Sources
 Table 102. Authors List of This Report


List of Figures
 Figure 1. PD-L1 Biomarker Testing Picture
 Figure 2. Global PD-L1 Biomarker Testing Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global PD-L1 Biomarker Testing Market Share by Type: 2024 VS 2031
 Figure 4. PD-L1 (22C3) Features
 Figure 5. PD-L1(28-8) Features
 Figure 6. PD-L1 (SP142) Features
 Figure 7. PD-L1 (SP263) Features
 Figure 8. Other Features
 Figure 9. Global PD-L1 Biomarker Testing Market Size by Application (2020-2031) & (US$ Million)
 Figure 10. Global PD-L1 Biomarker Testing Market Share by Application: 2024 VS 2031
 Figure 11. Hospital Case Studies
 Figure 12. Diagnostic Center Case Studies
 Figure 13. Others Case Studies
 Figure 14. PD-L1 Biomarker Testing Report Years Considered
 Figure 15. Global PD-L1 Biomarker Testing Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 16. Global PD-L1 Biomarker Testing Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 17. Global PD-L1 Biomarker Testing Market Share by Region: 2024 VS 2031
 Figure 18. Global PD-L1 Biomarker Testing Market Share by Players in 2024
 Figure 19. Global PD-L1 Biomarker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 20. The Top 10 and 5 Players Market Share by PD-L1 Biomarker Testing Revenue in 2024
 Figure 21. North America PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. North America PD-L1 Biomarker Testing Market Share by Country (2020-2031)
 Figure 23. United States PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Canada PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. Europe PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Europe PD-L1 Biomarker Testing Market Share by Country (2020-2031)
 Figure 27. Germany PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. France PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. U.K. PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Italy PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Russia PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Ireland PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. Asia-Pacific PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Asia-Pacific PD-L1 Biomarker Testing Market Share by Region (2020-2031)
 Figure 35. China PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Japan PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. South Korea PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Southeast Asia PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. India PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Australia & New Zealand PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Latin America PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Latin America PD-L1 Biomarker Testing Market Share by Country (2020-2031)
 Figure 43. Mexico PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Brazil PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East & Africa PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East & Africa PD-L1 Biomarker Testing Market Share by Country (2020-2031)
 Figure 47. Israel PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 49. UAE PD-L1 Biomarker Testing Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Agilent Technologies Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 51. Roche Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 52. Merck Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 53. Bristol-Myers Squibb Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 54. AstraZeneca Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 55. Ono Pharmaceutical Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 56. Regeneron Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 57. Innovent Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 58. Hengrui Medicine Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 59. Junshi Biosciences Revenue Growth Rate in PD-L1 Biomarker Testing Business (2020-2025)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global PD L1 and PIK3CA Testing Market Research Report 2024
PD L1 and PIK3CA Testing Product Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global PD L1 Biomarker Testing Platform Market Insights Forecast to 2030
Global PD 1 PD L1 Checkpoint Inhibitors Market Research Report 2024
Global PDL1 Antibody Reagent Immunohistochemistry Market Research Report 2024
IHC Detection Kits Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global PD 1 and PDL 1 Inhibitors Market Research Report 2025
Pd 1 and Pd L1 Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Immunohistochemistry Transmitter Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Checkpoint Inhibitors for Treating Cancer Market Insights Forecast to 2030
Immunohistochemistry IHC Antigen Retrieval Solution Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Immuno Oncology Assays Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
PD 1 and PD L1 Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immune Checkpoint Inhibitors for Cancer Market Research Report 2024
Global Immuno Oncology Assays Kit Market Insights Forecast to 2030
Global Combination Antibody Therapy Market Research Report 2024
Global PD 1 and PD L1 Monoclonal Antibody Market Research Report 2025
Global Automated IHC Staining System Market Research Report 2024
Global Immunoglobulin G Antibody Therapeutics Market Insights Forecast to 2030
Global Immunohistochemistry IHC Testing Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions